Female Comprehensive Hormone, Thyroid & CardioMetabolic Test | Specialist Doctor Report Included

Test ID: SB-652 | Saliva LCMS Hormones 7 with 4-Point Cortisol + Blood Spot Full Thyroid & CardioMetabolic Panel

The Female Comprehensive Hormone, Thyroid & CardioMetabolic Test is the most complete at-home health profile available for women anywhere in the UK, measuring 22 key hormones and markers across four interconnected systems in a single kit: sex hormone balance, the full daily cortisol stress rhythm, complete thyroid function including autoimmune antibodies, and a comprehensive cardiometabolic panel. It uses saliva LCMS (Liquid Chromatography–Mass Spectrometry) for sex hormones and cortisol — the gold standard for bioavailable hormone measurement — combined with a full blood spot thyroid and cardiometabolic panel.

This test exists because female health does not divide neatly into separate systems. In women, oestrogen, progesterone, cortisol, thyroid hormones, and insulin form a single integrated regulatory network — one in which disruption to any system cascades through all the others. Oestrogen protects cardiovascular health and maintains insulin sensitivity; its decline after menopause simultaneously raises LDL, suppresses HDL, elevates triglycerides, increases hsCRP, and impairs thyroid binding. Cortisol suppresses progesterone, impairs thyroid T3 conversion, drives insulin resistance, and promotes visceral fat — all simultaneously. Hashimoto’s thyroiditis produces symptoms identical to oestrogen deficiency, insulin resistance, and adrenal burnout — and is missed by TSH alone. And progesterone deficiency worsens all of these processes at every level.

No other single at-home test assesses all four of these systems together. This is it.

Test from home with confidence — no clinic visit required. Results within 3–5 working days.

The Female Hormonal-Metabolic System: Why All Four Must Be Tested Together

• Oestrogen is the primary coordinator of female metabolic and cardiovascular health — oestradiol maintains insulin sensitivity, HDL cholesterol, vascular elasticity, and systemic inflammation control via hsCRP; it supports thyroid hormone binding and T3 activity at the cellular level; and it regulates the hypothalamic-pituitary axis that governs the entire female reproductive and stress hormone cycle; its decline in perimenopause triggers simultaneous hormonal, thyroid, and cardiometabolic deterioration that no single-system test can fully characterise
• Cortisol is the central disruptor of all four systems in women — through pregnenolone steal, cortisol depletes progesterone, creating oestrogen dominance; it impairs T4-to-T3 conversion, creating functional hypothyroidism with normal TSH; it drives insulin resistance and visceral fat, raising triglycerides and suppressing HDL; and it elevates hsCRP, accelerating both hormonal ageing and cardiovascular risk; the 4-point cortisol profile is the essential lens through which all other results must be interpreted
• Thyroid dysfunction in women is systematically under-detected by TSH alone — cortisol-driven T3 suppression, oestrogen-related changes in thyroid hormone binding, and Hashimoto’s autoimmunity (present for years before TSH becomes abnormal) are all missed by standard thyroid screening; in women, thyroid dysfunction produces symptoms identical to oestrogen deficiency, insulin resistance, and adrenal burnout — making differentiation impossible without the full thyroid panel including FT3, FT4, TT4, TPO, and Tg antibodies
• Insulin resistance and cardiometabolic risk are hormonally driven in women at every life stage — PCOS is defined by insulin resistance even in lean women; the luteal phase reduces insulin sensitivity under progesterone; perimenopause removes oestrogen’s insulin-sensitising protection; postmenopause creates a sustained insulin-resistant, pro-inflammatory state; and hypothyroidism independently raises LDL, triglycerides, and hsCRP; only testing all four systems together reveals which hormonal drivers are active
• hsCRP is a stronger cardiovascular risk predictor in women than LDL — directly elevated by oestrogen decline, cortisol dysregulation, insulin resistance, Hashimoto’s autoimmunity, and progesterone deficiency; hsCRP is the convergence biomarker of the entire female hormonal-metabolic system and a primary target for integrated intervention

What This Test Measures — 22 Markers Across Four Systems

Saliva LCMS — Sex Hormones (6 markers)

• Oestradiol (E2): The primary premenopausal oestrogen — protecting cardiovascular health, bone density, insulin sensitivity, and mood stability. Declining E2 in perimenopause triggers hot flushes, night sweats, low mood, and the simultaneous cardiometabolic and thyroid vulnerability that characterises the menopausal transition. Measured by LCMS for the free, bioavailable fraction.
• Oestriol (E3): Reflects oestrogen conversion pathways and metabolic activity. The E3-to-E2 and E3-to-E1 ratios reveal how oestrogen is being processed and whether protective conversion pathways are functioning — relevant for cardiovascular and cancer risk assessment in women.
• Oestrone (E1): The dominant postmenopausal oestrogen, produced by adipose conversion of androgens. Elevated E1 in women with higher body fat or on HRT can drive oestrogen-dominant symptoms and metabolic inflammation; declining E1 in lean postmenopausal women reflects total oestrogenic deficit and accelerating cardiometabolic and thyroid vulnerability.
• Progesterone (Pg): The essential counterbalance to oestrogen and a key anti-inflammatory, cardioprotective, thyroid-supportive, and sleep-promoting hormone in women. Low progesterone — from anovulation, chronic stress, luteal phase deficiency, or perimenopause — drives oestrogen dominance, worsens insulin resistance, elevates hsCRP, and allows thyroid-suppressing cortisol to go unopposed.
• Testosterone (T): Essential in women for energy, libido, muscle mass, and metabolic rate. Low testosterone reduces lean mass, worsens insulin resistance, and impairs energy metabolism; elevated testosterone (as in PCOS) drives insulin resistance, visceral fat, and cardiometabolic risk directly. Measured by LCMS for bioavailable fraction accuracy.
• DHEAS (DS): The primary adrenal androgen precursor in women, declining from the mid-30s. Low DHEAS reduces testosterone and oestrogen precursor availability, impairs stress resilience, and has direct anti-inflammatory and insulin-sensitising effects. DHEAS decline is a primary contributor to the cardiometabolic deterioration of perimenopause and postmenopause.

Saliva — 4-Point Cortisol Profile (4 markers)

• Morning Cortisol: Sets insulin sensitivity, blood sugar, thyroid activation, and progesterone tone for the day. Exaggerated response drives morning insulin resistance and progesterone suppression; blunted response signals HPA burnout, impaired thyroid activation, and metabolic underperformance.
• Noon Cortisol: Elevated noon cortisol suppresses progesterone, impairs thyroid T3 conversion, drives visceral fat and insulin resistance, raises triglycerides, and promotes afternoon blood sugar instability — effects compounded in the luteal phase and perimenopause.
• Evening Cortisol: Should fall significantly to allow progesterone, melatonin, and growth hormone to rise — supporting thyroid cellular uptake, anti-inflammatory repair, and hormonal restoration overnight. Elevated evening cortisol prevents this shift and sustains the pro-inflammatory, insulin-resistant metabolic state.
• Night Cortisol: Elevated night cortisol suppresses deep sleep, prevents overnight fat metabolism, drives fasting insulin and hsCRP elevation, and directly worsens Hashimoto’s autoimmunity through sleep-deprivation-mediated immune dysregulation — a four-way attack on all systems this test measures simultaneously.

Blood Spot — Full Thyroid Panel (6 markers)

• TSH: Essential first-line thyroid marker — but misses cortisol-driven T3 suppression, oestrogen-related binding changes, and Hashimoto’s autoimmunity in women. Necessary but not sufficient.
• Free T3 (FT3): The active thyroid hormone — the most clinically important marker for women with thyroid symptoms and normal TSH. Low FT3 with normal TSH is the hallmark of cortisol-driven thyroid suppression and is missed by every standard NHS thyroid panel.
• Free T4 (FT4): The thyroid’s primary output hormone. Low FT4 with normal TSH indicates early thyroid insufficiency or impaired conversion — particularly relevant for women on HRT or the contraceptive pill, which increase thyroid-binding globulin.
• Total T4 (TT4): Provides full T4 context including bound fraction — important in women where oestrogen levels alter thyroid hormone binding and the free-to-total T4 ratio.
• TPO Antibodies (Anti-TPO): The primary diagnostic marker for Hashimoto’s thyroiditis in women. Elevated TPO antibodies frequently precede abnormal TSH by years, are associated with progressive thyroid decline, fatigue, weight gain, and depression, and are directly worsened by insulin resistance and cortisol dysregulation — both measured by this test.
• Thyroglobulin Antibodies (Anti-Tg): Essential second Hashimoto’s marker. Some women have elevated Tg antibodies with normal TPO — making both necessary for complete autoimmune thyroid assessment.

Blood Spot — CardioMetabolic Panel (6 markers)

• Fasting Insulin: The earliest detectable marker of insulin resistance in women — elevated years before HbA1c becomes abnormal. Directly driven by cortisol, low progesterone, oestrogen decline, and PCOS. In women, elevated fasting insulin promotes visceral fat, raises triglycerides, suppresses HDL, worsens thyroid antibody activity, and drives the PCOS hormonal cycle. The single most actionable early metabolic marker for women.
• HbA1c: Reflects average blood sugar over 8–12 weeks. Women’s diabetes risk rises markedly in perimenopause and postmenopause as oestrogen’s insulin-sensitising effects are lost; HbA1c contextualises the fasting insulin result with medium-term blood sugar trajectory.
• HDL Cholesterol: The protective cardiovascular fraction directly maintained by oestradiol. HDL falls significantly after menopause and with insulin resistance — a double impact in perimenopausal women. Also suppressed by hypothyroidism, which is directly assessed by this panel.
• Triglycerides: Elevated by cortisol, insulin resistance, oestrogen decline, and hypothyroidism simultaneously — four pathways all assessed by this test. A primary cardiometabolic risk marker particularly relevant for perimenopausal, postmenopausal, PCOS, and hypothyroid women.
• Total Cholesterol: Directly elevated by oestrogen decline and hypothyroidism — two of the most common hormonal changes in women. Rising cholesterol in perimenopausal or postmenopausal women is frequently a hormonal event rather than a dietary one, requiring integrated hormonal and metabolic assessment.
• hsCRP (High-Sensitivity C-Reactive Protein): The strongest independent predictor of cardiovascular disease in women — stronger than LDL. Elevated by oestrogen decline, cortisol dysregulation, insulin resistance, Hashimoto’s autoimmunity, and progesterone deficiency — all five of which are directly assessed by this panel. The convergence biomarker of the female hormonal-metabolic system.

Who Should Consider This Test?

This test is the ideal choice for women who experience any combination of:

• Persistent fatigue or exhaustion that does not improve with rest
• Unexplained weight gain or difficulty losing weight despite diet and exercise
• Sugar cravings, energy crashes, or afternoon slumps
• Elevated cholesterol, triglycerides, or blood sugar on previous testing
• PMS, heavy, irregular, or absent periods
• Perimenopausal or menopausal symptoms: hot flushes, night sweats, vaginal dryness, low mood
• Low libido or reduced sexual interest
• Brain fog, poor concentration, or memory issues
• Anxiety, irritability, or emotional volatility
• Hair thinning, dry skin, brittle nails, or feeling cold
• Insomnia, night waking, or unrefreshing sleep
• Diagnosed or suspected PCOS, Hashimoto’s thyroiditis, or oestrogen dominance
• Currently on HRT, the contraceptive pill, or thyroid medication
• Family history of thyroid disease, diabetes, heart disease, or metabolic syndrome
• Previous partial hormone or thyroid testing with inconclusive or incomplete results
• Women seeking the single most comprehensive at-home hormonal and metabolic health assessment available

Key Features

• 22-marker quad-system panel: saliva LCMS sex hormones, 4-point cortisol, full blood spot thyroid panel, and full cardiometabolic panel — the most comprehensive at-home female health test available in the UK
• Saliva LCMS — gold standard for bioavailable sex hormone measurement in women
• All three oestrogens (E1, E2, E3) for complete oestrogen metabolism, dominance, and conversion assessment
• Full 6-marker thyroid panel including TPO and Tg autoimmune antibodies
• 4-point cortisol profile — the essential lens for interpreting all other results
• Full 6-marker cardiometabolic panel including fasting insulin and hsCRP
• Results within 3–5 working days after lab receipt
• Expert analysis by a Hormone Specialist PhD Doctor
• Clear graphical and numerical results with personalised commentary
• All-inclusive price — laboratory fees included, no hidden costs
• Valid for 12 months from purchase

How It Works

1. Order the kit online — delivered directly to your door.
2. Collect your saliva samples at four time points (morning, noon, evening, night) for the sex hormone and cortisol panel, and your blood spot sample via a simple finger-prick for the thyroid and cardiometabolic panels, following the detailed instructions. Guidance on optimal cycle timing is included.
3. Post your samples to the lab using the return instructions in your kit.
4. Receive your results within 3–5 working days with specialist commentary and clear next-step guidance.

What Your Report Includes

• All 22 marker results with female-specific reference ranges
• Visual charts for all six sex hormones, your full 4-point cortisol daily curve, thyroid panel, and all six cardiometabolic markers
• Integrated clinical interpretation of how your sex hormones, cortisol, thyroid markers, and cardiometabolic results interact as a single female hormonal-metabolic system
• Oestrogen-progesterone dominance ratio analysis
• Cortisol-thyroid T3 conversion interaction assessment
• Insulin resistance pattern assessment (fasting insulin + HbA1c)
• Cardiovascular risk profile in full hormonal and thyroid context (HDL, triglycerides, cholesterol, hsCRP)
• Hashimoto’s autoimmunity assessment (TPO + Tg antibodies)
• Specialist commentary by a Hormone Specialist PhD Doctor
• Personalised next-step recommendations

Frequently Asked Questions

What does this test measure?

Oestradiol (E2), Oestriol (E3), Oestrone (E1), Progesterone, Testosterone, DHEAS (saliva LCMS) + 4-point Cortisol (saliva: morning, noon, evening, night) + TSH, Free T3, Free T4, Total T4, TPO Antibodies, Thyroglobulin Antibodies (blood spot) + Fasting Insulin, HbA1c, HDL Cholesterol, Triglycerides, Total Cholesterol, hsCRP (blood spot) — 22 markers in total.

Why is this test better than standard NHS blood tests for women?

Standard NHS testing typically measures total hormone levels by immunoassay, uses TSH as the sole thyroid marker, and does not assess cortisol rhythm, thyroid antibodies, fasting insulin, or hsCRP together. This test measures free, bioavailable hormone levels by LCMS, provides the full 4-point cortisol stress rhythm, screens for Hashimoto’s autoimmunity, and assesses insulin resistance and cardiovascular inflammation — revealing the hormonal root causes of symptoms that standard blood panels systematically miss in women.

When in my cycle should I collect?

Guidance on optimal cycle timing is included in your kit. For most women, collection in the luteal phase (days 19–21 of a 28-day cycle) provides the most clinically meaningful progesterone and oestrogen values alongside thyroid and cardiometabolic markers.

Can I use this test if I am on HRT, the contraceptive pill, or thyroid medication?

Yes. This test is particularly valuable for women on hormonal or thyroid treatment who want a complete picture of how their medication is affecting their entire hormonal, thyroid, and cardiometabolic system. HRT and the pill significantly affect oestrogen, progesterone, SHBG, thyroid binding, HDL, and triglycerides — all of which are directly assessed here. Follow the timing guidance in your kit.

Is this test suitable for women with PCOS or Hashimoto’s?

Yes — this test is particularly valuable for both conditions. PCOS is fundamentally a condition of insulin resistance, androgen excess, and oestrogen-progesterone imbalance, all directly assessed here. Hashimoto’s is screened by TPO and Tg antibodies alongside the full thyroid panel and the cortisol and insulin markers that drive autoimmune thyroid activity.

When will I get my results?

Within 3–5 working days after your samples reach the laboratory.

Are there hidden costs?

No. Laboratory analysis and specialist review are fully included. You are responsible for postage to the lab.

How long is the kit valid?

12 months from purchase.

Why We Partner with ZRT Laboratory

At Hormone Lab UK, every home test kit is analysed by ZRT Laboratory, a globally recognised, CLIA-certified diagnostic and research laboratory specialising in hormone testing, thyroid testing, fertility testing, adrenal function, neurotransmitter analysis, cardiometabolic health, heavy metals, and wellness testing. Founded in 1998 by renowned biochemist and breast cancer researcher Dr. David Zava, PhD, ZRT has become one of the world’s leading laboratories for advanced functional health testing.

With more than 11 million laboratory tests performed and healthcare professionals in over 96 countries relying on its expertise, ZRT is recognised for scientific excellence, analytical accuracy, and continuous innovation. The laboratory pioneered at-home saliva hormone testing, introduced the first commercially available dried blood spot (DBS) hormone tests, and developed Dried Urine Testing (DUTS), helping make advanced laboratory diagnostics more accessible and clinically meaningful.

Every sample is analysed using state-of-the-art LC-MS/MS and ICP-MS technology under rigorous quality control standards. ZRT collaborates with the CDC, NIH, and leading universities, supporting ongoing research and advances in laboratory medicine.